Статья
Обзор некоторых новейших научных исследований в области атеросклероза (По материалам докладов, представленных на 81-м Конгрессе Европейского атеросклеротического общества (EAS) 2–5 июня 2013 г., Лион, Франция)
Представлен обзор некоторых научных проблем, связанных с лечением и профилактикой атеросклероза, обсуждавшихся на 81-м Конгрессе Европейского атеросклеротического общества (EAS) 2–5 июня 2013 г., Лион, Франция.
1. Catapano A. L., Reiner Z., De Backer G. et al. ESC / EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Atherosclerosis. 2011. Vol. 217. P. 3–46.
2. Elkind M. S. Infectious burden: a new risk factor and treatment target for atherosclerosis // Infect Disord Drug Targets. 2010. Vol. 10. P. 84–90.
3. Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis // Future Cardiol. 2012. Vol. 8. P. 123–138.
4. Kozarov E., Kalachikov S., Morozov A., Chalmers N., Chien M. Metagenomics reveals gut signatures in atherosclerosis microbiome. EAS LYON 2013, Abstract 758.
5. Greiner T., Backhed F. Effects of the gut microbiota on obesity and glucose homeostasis // Trends Endocrinol. Metabol. 2011. Vol. 22. P. 117–123.
6. Kallus S. J., Brandt L. J. The intestinal microbiota and obesity // J. Clin. Gastroenterol. 2012. Vol. 46. P. 16–24.
7. Brady A. J., Perry C., Murdoch D. L., McKay G. Sustained benefits of a health project for middle-aged football supporters, at Glasgow Celtic and Glasgow Rangers Football Clubs // Eur Heart J. 2010. Vol. 31. P. 2696–2708.
8. Estruch R., Ros E., Salas-Salvado J. PREDIMED Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet // N. Engl. J. Med. 2013. Epub ahead of print 25 February.
9. Trichopoulou A., Bamia C., Trichopoulous D. Medi terranean diet and survival among patients with coronary heart disease in Greece // Arch. Intern. Med. 2005. Vol. 165. P. 929–356.
10. Giugliano D., Esposito K. Mediterranean diet and metabolic diseases // Curr. Opin. Lipidol. 2008. Vol. 19. P. 63–87.
11. Bozzetto L., Annuzzi G., Giacco R., Cipriano P., Mangione A., Costabile G., Anniballi G., Vetrani C., Conte F., Rivieccio A., Patti L., Riccardi G., Rivellese A.A. Diets rich in polyphenols and/or n-3 fatty acids reduce fasting and postprandial triglyceride-rich lipoproteins: the Etherpaths project // EAS Lyon. 2013. 2–5 June, Abstract book: 1576.
12. Costabile G., Annuzzi G., Bozzetto L., Della Corte G., Giacco A., Vitale M., Griffo E., Cocozza S., Della G., Pepa, Di Marino L., Pasanisi F., Riccardi G., Rivellese A. A. Effects of dietary polyphenols and/or n-3 fatty acids on oxidative stress in people at high car-dio vascular risk: the Etherpaths project // EAS Lyon 2013. 2–5 June, Abstract book: 1495.
13. Musa-Veloso K., Poon T. H., Elliot J. A., Chung C. A comparison of the LDL-cholesterol efficacy of plant stanols and plant sterols over a continuous range: Results of a meta-analysis of randomized, placebo-controlled trials // Prostaglandins Leukot Essent Fatty Acids. 2011. Vol. 85. P. 9–28.
14. Scholle J. M., Baker W. L., Talati R., Coleman C. I. The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis // J. Am. Coll. Nutr. 2009. Vol. 28. P. 517–524.
15. Demonty I., Ras R. T., van der Knaap H. C., Meijer L., Zock P. L., Geleijnse J. M., Trautwein E. A. The effect of plant sterols on serum triglyceride concentrations is dependent on baseline concentrations: a pooled analysis of 12 randomised controlled trials // Eur. J. Nutr. 2013. Vol. 52. P. 153–160.
16. Ference B. A., Yoo W., Alesh I. et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis // J. Am. Coll. Cardiol. 2012. Vol. 60. P. 2631–2639.
17. Wallner-Liebmann S. J., Siekmeier R., Grammer T. B., Mangge H., März W., Renner W. Smoking denial – an important cause of bias in cardiovascular studies // EAS Lyon. 2013, 2–5 June, Abstract book: 1625.
18. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. On behalf of EUROASPIRE Study Group. Cardiovascular prevention guidelines-the clinical reality: a comparison of EUROASPIRE I, II and III surveys in 8 European countries // Lancet 2009. Vol. 372. P. 929–940.
19. Zhang H., Plutzky J., Skentzos S. et al. Discontinuation of statins in routine care settings: a cohort study // Ann. Intern. Med. 2013. Vol. 158. P. 526–534.
20. Mansi I. A., Mortensen E. M., Pugh M. J., Wegner M., Frei C. R. Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis // Am. J. Med. Sci. 2013. Vol. 345. P. 343–348.
21. Farnier M., Averna M., Majul C. et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin up-titration or switching to rosuvastatin in patients with primary hypercholesterolemia at high cardiovascular risk (the EZ-Switch Study). Poster presented at EAS Lyon. 2013.
22. McKenney J. M., Koren M. J., Kereiakes D. J. et al. Safety and efficacy of a monoclonal antibody to pro protein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy // JACC. 2012. Vol. 59. P. 2344–2353.
23. Roth E. M., McKenney J. M., Hanotin C., Asset G., Stein E. A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367. P. 1891–1900.
24. Raal F., Scott R., Somaratne R., Bridges I., Li G., Wasserman S. M., Stein E. A. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin / kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDLC with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial // Circulation. 2012. Vol. 126. P. 2408–2417.
25. Raal F. J., Pilcher G. J., Panz V. R. et al. Reduction in mortality in subjects with homozygous familial hyper cholesterolemia associated with advances in lipid-lowering therapy // Circulation. 2011. Vol. 124. P. 2202–2207.
26. Stein E. A., Honarpour N., Wasserman S. M., Xu F., Scott R., Raal F. Trial evaluating AMG 145, a PCSK9 antibody, in patients with homozygous FH: results of an initial dose-scheduling study // EAS Lyon. 2013. 2–5 June, Abstract book: 1625.
27. Shamburek R., Bakker-Arkema R., Krause B., Auerbach B., Freeman L., Homan R., Asztalos B., Schaefer E., Schwartz C., Amar M. A., Remaley A. First report of enzyme replacement therapy in a patient with familial LCAT deficiency. Rapid improvement of lipid and clinical manifestations // EAS Lyon. 2–5 June, Abstract book: 1635.
28. Schwartz G. G., Olsson A. G., Abt M. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome // N. Engl. J. Med. 2012. Vol. 367. P. 2089–2099.
29. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment // Eur. Heart J. 2013. Vol. 341. P. 279–291.
30. Puri R., Nissen S. E. The complementary roles of imaging and ‘omics’ for future anti-atherosclerotic drug development // Curr. Pharm. Des. 2013. Feb. 15. [Epub ahead of print].